Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition

[1]  J. Vose,et al.  Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  I. Naito,et al.  Comparative analysis of basal lamina type IV collagen α chains, matrix metalloproteinases-2 and -9 expressions in oral dysplasia and invasive carcinoma. , 2013, Acta histochemica.

[3]  A. McBride,et al.  Proteasome inhibitors in the treatment of multiple myeloma , 2013, Expert review of anticancer therapy.

[4]  S. Pileri,et al.  Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study , 2013, Haematologica.

[5]  Li Wu,et al.  Convergent differentiation: myeloid and lymphoid pathways to murine plasmacytoid dendritic cells. , 2013, Blood.

[6]  S. Pileri,et al.  Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary. , 2012, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.

[7]  S. Pileri,et al.  Blastic plasmacytoid dendritic cell neoplasm: is it time to redefine the standard of care? , 2012, Expert review of hematology.

[8]  O. Grzybowska-Izydorczyk,et al.  Blastic plasmacytoid dendritic cell neoplasms – a report of two cases , 2012 .

[9]  S. Pileri,et al.  Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non‐haematopoietic tumours using a newly developed rabbit monoclonal antibody , 2012, Histopathology.

[10]  C. Chi,et al.  Mitochondrial dysfunction promotes cell migration via reactive oxygen species-enhanced β5-integrin expression in human gastric cancer SC-M1 cells. , 2012, Biochimica et biophysica acta.

[11]  K. Uzawa,et al.  Dermatopontin: A potential predictor for metastasis of human oral cancer , 2012, International journal of cancer.

[12]  M. Paulli,et al.  Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. , 2011, Blood.

[13]  N. Kadowaki,et al.  Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis. , 2011, Blood.

[14]  Xiaochu Yan,et al.  Blastic plasmacytoid dendritic cell neoplasm. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Inoue,et al.  Epigenetic alteration of the NF‐κB‐inducing kinase (NIK) gene is involved in enhanced NIK expression in basal‐like breast cancer , 2010, Cancer science.

[16]  M. Speicher,et al.  Alterations of the cell-cycle inhibitors p27(KIP1) and p16(INK4a) are frequent in blastic plasmacytoid dendritic cell neoplasms. , 2010, The Journal of investigative dermatology.

[17]  M. Angelopoulou,et al.  Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. , 2010, Leukemia research.

[18]  A. Kwiecińska,et al.  High resolution SNP array genomic profiling of peripheral T cell lymphomas, not otherwise specified, identifies a subgroup with chromosomal aberrations affecting the REL locus , 2010, British journal of haematology.

[19]  E. Jaffe,et al.  Plasmacytoid Dendritic Cells: Physiologic Roles and Pathologic States , 2009, Advances in anatomic pathology.

[20]  K. Anderson,et al.  The use of novel agents in the treatment of relapsed and refractory multiple myeloma , 2009, Leukemia.

[21]  W. Vermi,et al.  Blastic plasmacytoid dendritic cell neoplasm , 2009 .

[22]  R. Dalla‐Favera,et al.  Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma , 2009, Nature.

[23]  M. Reed,et al.  Senescence-induced alterations of laminin chain expression modulate tumorigenicity of prostate cancer cells. , 2008, Neoplasia.

[24]  Ø. Bruserud,et al.  Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels , 2008, Leukemia.

[25]  Zhiwei Wang,et al.  NF-κB Signaling Pathway and Its Therapeutic Implications in Human Diseases , 2008, International reviews of immunology.

[26]  K. Akashi,et al.  The developmental program of human dendritic cells is operated independently of conventional myeloid and lymphoid pathways. , 2007, Blood.

[27]  L. Staudt,et al.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.

[28]  R. Willemze,et al.  Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. , 2007, Blood.

[29]  F. Garnache-Ottou,et al.  Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity? , 2007, British journal of haematology.

[30]  C. Massone,et al.  CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer , 2006, Journal of Clinical Pathology.

[31]  V. Soumelis,et al.  From plasmacytoid to dendritic cell: Morphological and functional switches during plasmacytoid pre‐dendritic cell differentiation , 2006, European journal of immunology.

[32]  M. Karin.  Nuclear factor-κB in cancer development and progression , 2006, Nature.

[33]  S. Ikehara,et al.  Plasmacytoid Dendritic Cells of Different Origins Have Distinct Characteristics and Function: Studies of Lymphoid Progenitors versus Myeloid Progenitors , 2005, The Journal of Immunology.

[34]  T. Stokke,et al.  Translocation t(14;18) and gain of chromosome 18/BCL2: effects on BCL2 expression and apoptosis in B-cell non-Hodgkin's lymphomas , 2005, Leukemia.

[35]  J. Benítez,et al.  Differential expression of NF-κB pathway genes among peripheral T-cell lymphomas , 2005, Leukemia.

[36]  H. Stauss,et al.  Antigen-specific cellular immunotherapy of leukemia , 2005, Leukemia.

[37]  R. Larson,et al.  CD4(+) CD56(+) Lineage-Negative Malignancies Are Rare Tumors of Plasmacytoid Dendritic Cells , 2005, The American journal of surgical pathology.

[38]  M. Teitell,et al.  Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. , 2005, American journal of clinical pathology.

[39]  N. Panoskaltsis,et al.  Dendritic cells in MDS and AML – cause, effect or solution to the immune pathogenesis of disease? , 2005, Leukemia.

[40]  M. Tomonaga,et al.  A Novel Plasmacytoid Dendritic Cell Line, CAL-1, Established from a Patient with Blastic Natural Killer Cell Lymphoma , 2005, International journal of hematology.

[41]  C. Caux,et al.  In situ leukemic plasmacytoid dendritic cells pattern of chemokine receptors expression and in vitro migratory response , 2004, Leukemia.

[42]  M. Matsuoka,et al.  Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro , 2004, Leukemia.

[43]  S. Willis,et al.  The Bcl-2-regulated apoptotic pathway , 2003, Journal of Cell Science.

[44]  M. Callanan,et al.  CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique. , 2002, Blood.

[45]  B. Drénou,et al.  Clinical and biologic features of CD4(+)CD56(+) malignancies. , 2002, Blood.

[46]  A. Lanzavecchia,et al.  Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization , 2000, Nature Immunology.

[47]  P. Minoprio.  Lymphocytes: A Practical Approach (2nd edn) by S.L. Rowland-Jones and A.J. McMichel , 2000 .

[48]  T. Molina,et al.  CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Français d'Etude des Lymphomes Cutanés (GFELC). , 1999, The American journal of surgical pathology.

[49]  J. Banchereau,et al.  The Enigmatic Plasmacytoid T Cells Develop into Dendritic Cells with Interleukin (IL)-3 and CD40-Ligand , 1997, The Journal of experimental medicine.

[50]  K. Welte,et al.  Generation and characterization of a novel hematopoietic progenitor cell line with DC differentiation potential , 2012, Leukemia.

[51]  M. Wang,et al.  Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy , 2009, Leukemia.

[52]  F. Jardin,et al.  Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease , 2009, Leukemia.

[53]  S. Lade,et al.  Primary cutaneous CD4+/CD56+ hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases. , 2006, Haematologica.

[54]  M. Karin.  Nuclear factor-kappaB in cancer development and progression. , 2006, Nature.

[55]  P. Tassone,et al.  NF-κB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors , 2004, Leukemia.

[56]  B. Aggarwal,et al.  Nuclear transcription factor-kappaB as a target for cancer drug development. , 2002, Leukemia.

[57]  A Garg,et al.  Nuclear transcription factor-κB as a target for cancer drug development , 2002, Leukemia.

[58]  J C Reed,et al.  Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death. , 1996, Advances in experimental medicine and biology.

[59]  G. Klaus.  Lymphocytes : a practical approach , 1987 .